Digital Medicine Society (DIME) has announced that it is partnering with Alcohol and Drug Services (ADS), Duke University, Google Fitbit, Morse Clinics, North Carolina Central University, Ourura, Proofpilot, Triangle Cersi and North Carolina University at Chapel Hill (UNC).
The purpose of this partnership is to reduce the deaths of opioid use disorder (OUD) by using data collected from consumer wearables to create interventions to prevent recurrence.
According to 2023 National Survey on Drug Use and Health According to the Substance Abuse and Mental Health Services Agency (SAMHSA), in 2023, 2.0% (or 5.7 million) of people over the age of 12 had opioid use disorders over the past year.
Partners can work together to explain and collect physiological signals and behavioral traits, such as heart rate, insomnia, physical inactivity, and physiological stress, to predict recurrence and measure it using wearable techniques.
Using smartphones, researchers collect mental health characteristics such as social isolation, patient-reported anxiety and depression. Data Points train tools to prevent opioid recurrence.
The team will conduct a collaborative study led by Duke University’s Big Ideas Lab to enroll patients for pilot studies to test their approaches, ensuring that the method obtains optimal quality data to develop recurrence prevention tools.
“OUD is a complex challenge, and complex challenges require innovative collaboration and solutions,” said Candice Taguibo, Associate Program Director at DIME in a statement.
“Our teams are embracing a number of issues for people facing OUD, including mental health, social support, treatment options, finances, access to technology, social stigma and more.
Shyamal Patel, Senior Vice President of Science at Oura, argued that by leveraging technological advances to develop evidence-based protocols for those living with OUD, they position these interventions for success.
“We are proud to support this research by providing continuous health surveillance and personalized, data-driven insights, which will allow individuals to take proactive steps to recovery, reduce the burden on potentially growing public health systems and provide important tools in the fight against the opioid epidemic,” Patel said.
Bigger trends
March, Dime and Google Health introduced it Free online courses To help health professionals, researchers, administrators and innovators learn the fundamentals of use cases in generative AI, large-scale language models (LLM), and technology healthcare.
Healthcare Course Generation AI provides stakeholders with an understanding of LLMS and applications in healthcare. Additionally, participants will gain insight into generative AI technologies, develop rapid engineering skills, and explore how AI can support decision-making in a clinical setting.
2024, rKorean esearchers have built a machine learning-based model that can predict mood episodes using only sleep and circadian rhythm data from wearable devices.
The team consisted of researchers from the Institute of Basic Science (IBS), the Institute of Advanced Science and Technology (KAIST), and the Faculty of Medicine at the University of Korea.
A study published in Nature’s The Digital Medicine Journal and the research team first collected and analyzed 429 days of sleep-wake data generated from Fitbits of 168 Korean patients with mood disorders, including major depression and bipolar disorder.
The researchers extracted 36 sleep and circadian rhythm features from this dataset and were then applied to predict mood episodes to train models based on the machine learning library xgboost.
The findings revealed that the predictive models achieved 80%, 98%, and 95% accuracy in predicting depressive episodes, man’s disease, and mild many positive episodes, respectively.
That same year, Wella has closed a $200 million Series D funding round led by Fidelity Management & Research Company and Dexcom. The investment has raised the company’s valuation to $5.2 billion.
In November 2024, Dexcom created a The $75 million strategic investment has established a strategic partnership that enables two-way data flow between Dexcom’s continuous glucose monitor (CGM) and Oura Ring. The investment at the time made Ula valuation more than $5 billion.
